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Introduction 
Over 75% of the total population experiences at least one 
episode of low back pain (LBP) during their lifetime, and 
its annual prevalence has been reported to be 15%–45% 
[1]. In the Korea National Health and Nutrition Exami-
nation Survey in 2007, 15.4% of adults aged 20–89 years 
reported experiencing LBP, and 5.7% reported having 
chronic LBP (CLBP) that lasted for more than three 
months during the past year. An estimated 2,060,829 Ko-
reans experienced CLBP in 2007, which is an incidence 
much higher than that observed in other chronic diseases 
[2]. 
Freynhagen and Baron reported that 20%–35% of pa-
tients with LBP reported accompanying neuropathic pain 
(NP) [3]. The International Association for the Study of 
Pain defined NP as pain initiated or caused by a primary 
lesion or dysfunction in the nervous system [4]. NP oc-
curs when normal inflammatory responses are directed 
toward the body in a harmful manner [5]. The normal 
function of the inflammatory response is to remove 
damaged nerves, promote nerve regeneration, and de-
liver inflammatory chemokines to neuronal cell bodies, 
thereby stimulating proximal nociceptors and causing 
pain without tissue damage [6]. NP can arise from the 
overstimulation of pain-transmitting neuronal cell bodies 
and the structural alteration of synapses in the cornu of 
the spinal cord, interneurons, and glial cells, resulting in 
the development of chronic pain [5]. The characteristic 
clinical symptoms of NP are continuous or spontaneously 
provoked pain [7]. Sometimes, the pain is accompanied 
by sensations of burning, soreness, stinging, tingling, and 
hypoesthesia or dysesthesia due to neural damage [7]. 
Motor paralysis, cramping, and other symptoms of the 
autonomic nervous system have also been observed to ac-
company pain in damaged areas [7]. 
Recently, there have been various reports on the impact 
of chronic and refractory NP on the quality of life (QoL) 
and dysfunction. One review reported that NP had a neg-
ative effect on the QoL, which became more aggravated 
as NP became more severe [8]. Further, when NP accom-
panied various diseases, such as diabetes [9], spinal cord 
Study Design: A noninterventional, multicenter, cross-sectional study.
Purpose: We investigated the prevalence of neuropathic pain (NP) and patient-reported outcomes (PROs) of the quality of life (QoL) 
and functional disability in Korean adults with chronic low back pain (CLBP).
Overview of Literature: Among patients with CLBP, 20%–55% had NP.
Methods: Patients older than 20 years with CLBP lasting for longer than three months, with a visual analog scale (VAS) pain score 
higher than four, and with pain medications being used for at least four weeks before enrollment were recruited from 27 general 
hospitals between December 2014 and May 2015. Medical chart reviews were performed to collect demographic/clinical features 
and diagnosis of NP (douleur neuropathique 4, DN4). The QoL (EuroQoL 5-dimension, EQ-5D; EQ-VAS) and functional disability (Quebec 
Back Pain Disability Scale, QBPDS) were determined through patient surveys. Multiple linear regression analyses were performed to 
compare PROs between the NP (DN4≥4) and non-NP (DN4<4) groups.
Results: A total of 1,200 patients (females: 65.7%; mean age: 63.4±13.0 years) were enrolled. The mean scores of EQ-5D, EQ-VAS, 
and QBPDS were 0.5±0.3, 55.7±19.4, and 40.4±21.1, respectively. Among all patients, 492 (41.0%; 95% confidence interval, 38.2%–
43.8%) suffered from NP. The prevalence of NP was higher in male patients (46.8%; p<0.01), in patients who had pain based on radio-
logical and neurological findings (59.0%; p<0.01), and in patients who had severe pain (49.0%; p<0.01). There were significant mean 
differences in EQ-5D (NP group vs. non-NP group: 0.4±0.3 vs. 0.5±0.3; p<0.01) and QBPDS (NP group vs. non-NP group: 45.8±21.2 vs. 
36.3±20.2; p<0.01) scores. In the multiple linear regression, patients with NP showed lower EQ-5D (β=−0.1; p<0.01) and higher QBPDS 
(β=7.0; p<0.01) scores than those without NP.
Conclusions: NP was highly prevalent in Korean patients with CLBP. Patients with CLBP having NP had a lower QoL and more severe 
dysfunction than those without NP. To enhance the QoL and functional status of patients with CLBP, this study highlights the impor-
tance of appropriately diagnosing and treating NP.
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injury [10], and cancer [11], various aspects of the QoL 
were negatively affected. While the pain itself reduces the 
QoL, the dysfunction caused by this pain affects depres-
sion and the QoL [12]. In particular, CLBP causes a high 
absenteeism rate from work due to dysfunction; further, it 
shows a low cure rate and high relapse rate [13].
The early diagnosis of NP and active pain control are 
essential for the QoL and functional improvement of pa-
tients with CLBP. However, there has been no consensus 
regarding the definition of NP and its diagnostic criteria 
in patients with CLBP. Further, there have been no data 
regarding the prevalence of NP in Korean patients with 
CLBP, their QoL, or the level of dysfunction. Therefore, 
the purpose of this study was to quantify these character-
istics.
Materials and Methods
1. Subject recruitment
This was a noninterventional, multicenter, cross-sectional 
observational study conducted in the orthopedic surgery 
and neurosurgery departments of 27 general hospitals 
in Korea from December 2014 to May 2015. The inclu-
sion criteria were as follows: (1) patients aged 20 years or 
older; (2) patients diagnosed with LBP due to herniated 
disc, stenosis, spondylosis, spondylolysis, spondylolisthe-
sis, or degenerative disc disease, according to magnetic 
resonance imaging or computed tomography findings; 
(3) patients with LBP (pain or symptoms) lasting for at 
least three months; (4) patients with LBP rated as ≥4 of 
10 points on a pain visual analog scale (VAS); (5) patients 
who received LBP-related drug therapy for over four 
weeks; and (6) patients who were able to understand and 
willing to complete the subject information sheet and in-
formed consent form. The exclusion criteria as follows: (1) 
patients with LBP due to sprain, trauma, ankylosing spon-
dylitis, myofascial pain, or sacroiliitis; (2) patients with 
LBP rated as <4 points on the VAS; (3) patients with LBP 
lasting for less than three months; (4) patients who had 
undergone any surgery within the past three months; (5) 
patients participating in another clinical study (interven-
tional study); (6) patients with a critical or unstable health 
condition; or (7) patients otherwise determined unfit for 
inclusion or analysis by clinicians. A total of 1,200 patients 
who met the selection criteria were included.
2. Sample size estimation
A target sample size was estimated based on the assump-
tion that the prevalence of neuropathic LBP (NLBP) is 
37% [14]. With a significance level of 0.05 and an esti-
mated error rate of 2.8%, the required number of patients 
to be enrolled was calculated to be approximately 1,200: 
n=z21−α/2P (1−P)/d2 [15] (P=0.37; z21−α/2=1.962, when α is 
0.05; d=0.028). 
3. Study data
Study data were collected from patient medical records 
and patient surveys with a questionnaire. Medical chart 
reviews were conducted to collect demographic char-
acteristics (age, sex, height, and body weight), clinical 
characteristics (diagnosis of LBP, comorbidities, symptom 
period, VAS scores, and The Quebec Task Force Classifica-
tion for Spinal Disorders [QTFC-SD]), pain control state 
(pharmacotherapy and surgery), and diagnosis of NP. 
NLBP as a NP group was defined as a score of ≥4 points 
on the douleur neuropathique 4 (DN4) questionnaire, 
which is a set of four questions on sensory descriptors 
and signs associated with sensory examination and has 
a total score range of 0 to 10 points [16]. This question-
naire is simple and includes discriminant items requiring 
yes or no responses. Two questions (I and II) are based 
on the patient’s interview and the other questions (III and 
IV) are grounded on a standardized clinical examination 
[16]. QTFC-SD was mainly designed to be practical and 
comprised six questions. Patient classification for each 
question is as follows: Q1, patients who reported only 
back pain; Q2, patients without neurologic findings but 
reporting pain extend above the knee only; Q3, those with 
pain extending to the calf or foot; Q4, patients with pain 
traveling to the leg and positive neurologic findings; Q5, 
patients meeting criteria for Q4 and having lumbar disc 
disease with nerve root compression on conducting an 
imaging study; and Q6, those diagnosed with spinal ste-
nosis regardless of having lumbar disc disease [17]. 
The QoL and degree of dysfunction were evaluated 
through self-administered questionnaires. The QoL was 
assessed with the EuroQoL 5-dimension (EQ-5D) ques-
tionnaire and EQ-VAS; higher scores imply a higher QoL 
in both tools (EQ-5D, −0.229–1 point; EQ-VAS, 0–100 
points). The EQ-5D was composed of a total of five ques-
tions, and the scale used in the health state description 
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part had three levels: having no problems, having some 
or moderate problems, and being unable to do/having ex-
treme problems. The rated level could be coded as a num-
ber: 1, having no problems; 2, having some problems; and 
3, having extreme problems. The measured EQ-5D items 
were converted to scores [18] using the following equa-
tion:
Final EQ-5D score [18]=1−(0.165+0.003×M2+0.274×M
3+0.058×SC2+0.078×SC3 +0.045×UA2+0.133×UA3+0.04
8×PD2+0.130×PD3+0.043×AD2+0.103×AD3+0.347×N3
+0.014×I2sq)
The degree of dysfunction was measured using the 
Quebec Back Pain Disability Scale (QBPDS), which is 
composed of 20 questions with a scale of 0 to 5 for each 
question and a total score ranging from 0 to 100 points. A 
higher score indicates more severe dysfunction (for more 
information about the QBPDS, see the footnote in Fig. 1).
4. Study ethics
The patients (or their legal representatives) were provided 
with all study-related information, and they signed an 
informed consent form. All participating medical institu-
tions obtained approval from their respective institutional 
review boards. 
5. Statistical analysis
Patient demographics and clinical characteristics are sum-
marized as mean±standard deviation for continuous vari-
ables or frequency (percentage) for categorical variables. 
Prevalence rates of NP by patient characteristics were 
compared using the χ2 test, while the QoL and degree of 
dysfunction between the NP and non-NP groups were 
compared using Student’s t-test. To examine whether NP 
is associated with either QoL or the severity of dysfunc-
tion, multiple linear regression analysis was performed 
with adjustment for effects of potential confounders. Vari-
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Fig. 1. Differences between the NP and non-NP groups on the quality of life and level of functional disability. (A) Proportion of Level 3 (a lot of 
problems) in response to each EQ-5D dimension. (B) Proportion of level 4 and 5 (very difficult & unable to do) in response to each QBPDS item. NP, 
neuropathic pain; EQ-5D, Euro quality of life 5-dimension; QBPDS, Quebec Back Pain 6 Disability Scale; Item 1, get out of bed; Item 2, sleep through 
the night; Item 3, turn 7 over in bed; Item 4, ride in a car; Item 5, stand up for 20–30 minutes; Item 6, sit in a chair for several hours; Item 7, climb 
one flight of stairs; Item 8. walk a few blocks (300–400 m); Item 9, walk several kilometers; Item 10, reach up to high shelves; Item 11, throw a ball; 
Item 12, run one block (about 100 m); Item 13, take food 10 out of the refrigerator; Item 14, make your bed; Item 15, put on socks (pantyhose); Item 
16, bend over to clean 11 the bathtub; Item 17, move a chair; Item 18, pull or push heavy doors; Item 19, carry two bags of groceries; Item 20, lift 
and carry a heavy suitcase.  a)p<0.01; b)p<0.05. 
Prevalence of NP and PROs in CLBP patientsAsian Spine Journal 921
ables with p-values of <0.1 in bivariate analyses were se-
lected for adjustment in the multivariable model. All sta-
tistical analyses were performed using the SAS software, 
version 9.4 (SAS Institute, Inc., Cary, NC, USA), and two-
tailed p-values less than 0.05 were considered statistically 
significant.
Results
1. Characteristics of patients with CLBP
The mean age of the patients was 63.4±13.0 years. Most 
patients (65.7%) were females and 702 (58.5%) had one 
or more comorbidities. The most common comorbidity 
was hypertension (44.1%); this was followed by diabetes 
(19.5%). Rheumatoid arthritis (3.2%) was the least fre-
quent comorbidity. The mean pain VAS score in patients 
with CLBP was 6 points. The mean duration of pain was 
four years and two months, and the mean duration of 
disease after diagnosis was one year and five months. The 
most frequently diagnosed condition was stenosis (47%), 
and the most frequent pain type identified by the QTFC-
SD was pain with distal extremity radiation (40%; Table 1). 
 
2. NP prevalence in patients with CLBP 
The mean DN4 score was 3.4±2.0 points. Among the subi-
tems, the most common response was “pain related with 
tingling symptoms in the same area (22.4%)” (Fig. 2).
The NP prevalence was 41% (95% confidence interval, 
38.2%–43.8%). NP was more prevalent in males. Among 
the QTFC-SD items, the proportions of patients with 
radiating pain and NP were higher than those of patients 
with other types of pain. Patients with severe pain (VAS 
scores, 7–10) had a higher prevalence of NP than those 
with moderate pain (VAS scores, 4–6) (Table 2).
Table 1. Characteristics of chronic low back pain patients (n=1,200)
Characteristics Value Characteristics Value
Age (yr)   63.4±13.0 Detailed diagnosisa)
Body mass index (kg/m2) 24.3±3.1 Herniated disc    376 (23.2)
Sex Stenosis    761 (47.0)
Female     788 (65.7) Spondylosis 130 (8.0)
Male     412 (34.3) Spondylolysis    25 (1.5)
Comorbidities Spondylolisthesis    207 (12.8)
No     498 (41.5) Degenerative disc disease  119 (7.4)
Yes     702 (58.5) QTFC-SD
Type of comorbid diseasea) Pain without radiation    180 (15.0)
Depression     41 (3.6) Pain with proximal extremity radiation    207 (17.3)
Diabetes     222 (19.5) Pain with distal extremity radiation    478 (39.8)
GI disease    93 (8.2) Pain with radiation and neurologic finding   83 (6.9)
Hypertension    502 (44.1) Spinal nerve root compression 101 (8.4)
Heart disease    125 (11.0) Spinal stenosis    151 (12.6)
Rheumatoid arthritis     36 (3.2) Pharmacological medicationsa)
Thyroid disease     63 (5.5) Non-opioid analgesics  1058 (54.5)
Pain VAS (score)   6.1±1.6 Opioid analgesics  165 (8.5)
Pain duration (mo)   50.2±68.2 Anticonversants    220 (11.3)
LBP duration from the diagnosis (day)   506.7±746.0 Antidepressants    92 (4.7)
Muscle relaxants    326 (16.8)
Lidocaine    81 (4.2)
Values are presented as mean±standard deviation or number (%).
QTFC-SD, The Quebec Task Force Classification for Spinal Disorders; GI, gastrointestinal; VAS, visual analogue scale; LBP, low back pain.
a)Multiple responses item.
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3. QoL and dysfunction in patients with CLBP
The mean EQ-5D, EQ-VAS, and QBPDS scores in pa-
tients with CLBP were 0.5±0.3, 55.7±19.4, and 40.4±21.1 
points, respectively. Between the NP and non-NP groups, 
significant mean differences were found in the EQ-5D 
(NP group vs. non-NP group: 0.4±0.3 vs. 0.5±0.3; p<0.01) 
and QBPDS (NP group vs. non-NP group: 45.8±21.2 vs. 
36.3±20.2; p<0.01) scores. No significant mean difference 
in the EQ-VAS score between the two groups was shown 
(NP group vs. non-NP group: 54.7±20.0 vs. 56.7±18.9; 
p=0.07) (Fig. 3). The percentages of patients with NP who 
Fig. 3. Quality of life and functional disability in patients with chronic low back pain. (A) EQ-5D. (B) EQ-VAS. (C) QBPDS. NP, neuropathic pain; PRO, 
patient reported outcome; EQ-5D, Euro quality of life 5-dimension; EQ-VAS, Euro quality of life visual analog scale; QBPDS, quebec back pain dis-
ability scale. a)p-value by Student’s t-test; b)Values given as mean±standard deviation. 
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Fig. 2. Neuropathic pain in patients with chronic low back pain (n=1,200). DN4, douleur neuropathique 4; SD, standard deviation. a)Mul-
tiple responses item.
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Table 2. Prevalence of neuropathic pain in chronic low back pain patients
Characteristics Total NP Prevalence (%) (95% CI) p-valuea)
Total 1,200 492 41.0 (38.2, 43.8)
Sex 0.003
Female 788 299 37.9 (34.5, 41.4)
Male 412 193 46.8 (41.9, 51.8)
Age (yr) 0.319
20–29 30 16 53.3 (34.3, 71.7)
30–39 42 19 45.2 (29.8, 61.3)
40–49 93 35 37.6 (27.8, 48.3)
50–59 224 103 46.0 (39.3, 52.7)
60–69 363 142 39.1 (34.1, 44.3)
≥70 448 177 39.5 (35.0, 44.2)
Body mass index (kg/m2) 0.292
Low weight (<18.5) 22 8 36.4 (17.2, 59.3)
Normal (18.5≤, <22.9) 336 126 37.5 (32.3, 42.9)
Over weight (23≤, <25) 257 103 40.1 (34.0, 46.3)
Obesity (25≤) 407 180 44.2 (39.3, 49.2)
Comorbidities 0.537
No 498 199 40.0 (35.6, 44.4)
Yes 702 293 41.7 (38.1, 45.5)
Type of comorbiditiesb) -
COPD 11 6 54.5 (23.4, 83.3)
Depression 41 21 51.2 (35.1, 67.1)
Diabetes 222 94 42.3 (35.8, 49.1)
GI disease 93 48 51.6 (41.0, 62.1)
Hypertension 502 207 41.2 (36.9, 45.7)
Inflammation 10 9 90.0 (55.5, 99.7)
Thyroid disease 63 27 42.9 (30.5, 56.0)
Psychosis 9 4 44.4 (13.7, 78.8)
Detailed diagnosis b) -
Herniated disc 376 189 50.3 (45.1, 55.4)
Stenosis 761 321 42.2 (38.6, 45.8)
Spondylosis 130 42 32.3 (24.4, 41.1)
Spondylolysis 25 13 52.0 (31.3, 72.2)
Spondylolisthesis 207 75 36.2 (29.7, 43.2)
Degenerative disc disease 119 54 45.4 (36.2, 54.8)  
QTFC-SD <0.001
Pain without radiation 180 27 15.0 (10.1, 21.1)
Pain with proximal extremity radiation 207 70 33.8 (27.4, 40.7)
Pain with distal extremity radiation 478 247 51.7 (47.1, 56.2)
Pain with radiation and neurologic finding 83 49 59.0 (47.7, 69.7)
Spinal nerve root compression 101 41 40.6 (30.9, 50.8)
Spinal stenosis 151 58 38.4 (30.6, 46.7)
(Continued to the next page)
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was the highest in item 12: Run one block (approximately 
100 m; 15.0%) followed by item 20, moving heavy travel 
luggage (56.2%). Item 13, taking out foods from the re-
frigerator (7.3%), showed the lowest proportion. The re-
sponses to the QBPDS questionnaire are summarized in 
Fig. 1B.
After adjustment with confounding variables, the NP 
group had significantly lower EQ-5D (β=−0.1; p<0.01) 
and significantly higher QBPDS (β=7.0; p<0.01) scores 
than the non-NP group. While there was no significant 
difference in the EQ-VAS scores between the two groups, 
the EQ-VAS score was lower in the NP group than in the 
non-NP group (β=−2.6; p=0.059) (Table 3).
Discussion
This study revealed a high NP prevalence (41.0%) based 
on the DN4 questionnaire in Korean patients with CLBP. 
Similar results have been identified in other studies. In 
Turkey, NP prevalence in patients with CLBP was 39.4% 
in 2014 as measured by the Leeds Assessment of Neuro-
answered level 3 (a lot of problems) in each dimension of 
EQ-5D were pain/discomfort (36.2%), anxiety/depression 
(10.7%), usual activities (10.5%), mobility (5.0%), and 
self-care (4.1%) (Fig. 1A). In the NP group, the propor-
tion of patients who responded “I was very uncomfortable 
or unable to do any activity in each item of the QBPDS” 
Table 3. Quality of life and functional disability in chronic low back 
pain with neuropathic pain
PRO Coeff. SE Std. Coeff. p-valuea)
EQ-5Db) –0.081 0.017 –0.147 <0.0001
EQ-VASb) –2.620 1.386 –0.066 0.059
QBPDSb) 7.005 1.410 0.161 <0.0001
PRO, patient reported outcome; Coeff., coefficient; SE, standard er-
ror; Std. Coeff., standardized coefficient; EQ-5D, Euro quality of life 
5-dimension; EQ-VAS, Euro quality of life visual analog scale; QBPDS, 
quebec back pain disability scale.
a)p -value by multiple linear regression analysis; b)Reference group: 
non-neuropathic pain patients; adjusted variables were sex, age, 
Quebec Task Force Classification for Spinal Disorders, duration of LBP 
after diagnosis, pain visual analog scale.
Characteristics Total NP Prevalence (%) (95% CI) p-valuea)
LBP duration from the diagnosis (wk) 0.669
Acute (<6) 221 94 42.5 (35.9, 49.3)
Subacute (6≤, <12) 76 28 36.8 (26.1, 48.7)
Chronic (12≤) 595 240 40.3 (36.4, 44.4)
Pain VAS (score) <0.001
Moderate (VAS scores: 4–6) 739 266 36.0 (32.5, 39.6)
Severe (VAS scores: 7–10) 461 226 49.0 (44.4, 53.7)
Pain duration (mo) 0.550
<10 281 108 38.4 (32.7, 44.4)
10 to 23 228 95 41.7 (35.2, 48.4)
24 to 59 345 136 39.4 (34.2, 44.8)
60≤ 346 153 44.2 (38.9, 49.6)
Medications for pain controlb) -
Non-opioid analgesics 1058 433 40.9 (37.9, 44.0)
Opioid analgesics 165 79 47.9 (40.1, 55.8)
Anticonversants 220 102 46.4 (39.6, 53.2)
Antidepressants 92 40 43.5 (33.2, 54.2)
Muscle relaxants 326 140 42.9 (37.5, 48.5)
Lidocaine 81 35 43.2 (32.2, 54.7)
NP, neuropathic pain; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; QTFC-SD Quebec Task Force Clas-
sification for Spinal Disorders; LBP, low back pain; VAS, visual analog scale. a)p-value by chi-square test; b)Multiple responses item.
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pathic Symptoms and Signs (LANSS) [19], and a multi-
center study in Saudi Arabia found a prevalence of 54.7%, 
also measured by the LANSS [20]. In a multicenter Japa-
nese study of patients with spinal disorder having chronic 
pain, the prevalence of NP was 53.3%, as assessed by an 
NP screening questionnaire [21]; this study included as-
sessments of lumbar/sacral and cervical levels. If cervical 
and thoracic levels were also considered for our patients, 
a higher NLBP prevalence would have been obtained. An 
American study using the PharMetrics IMS LifeLinkTM 
US Claims Database (2006–2008) found an NLBP preva-
lence of 90.4% based on ICD-9 codes, indicating that 
almost all patients with CLBP had NP [22]. Given the 
substantial differences in the methods of diagnosis for NP, 
direct comparisons with the prevalence of NLBP reported 
in other studies are limited.
Numerous factors increased NP prevalence in patients 
with CLBP. There was a higher prevalence of NP in males 
in the present study. This is because men tended to spend 
a longer time at work [23]. The prevalence of NP in the 
young population was higher than in patients aged 65 
years and older, which is similar to the findings of Sakai et 
al. [24] Inflammation and chronic obstructive pulmonary 
disease, in particular, increased NP prevalence, suggest-
ing that patients with low immunity or abnormal immune 
status are more prone to NP [25]. Regarding the primary 
diagnosis, NP was common in patients with spondyloly-
sis, herniated disc, and degenerative disc disease, which 
suggests that diseases that directly damage the nerves 
have a higher NP incidence. Of the types of pain assessed 
by the QTFC-SD, there was a higher prevalence of NP in 
patients who reported radiating pain. Further, it seems 
that items in the QTFC-SD that are related to pain in the 
lower limbs are more helpful for accurately diagnosing 
NP than items related to lower back pain [26]. As pain 
became more severe, NP prevalence increased, which was 
consistent with the results of a previous study [27]. Finally, 
as the disease duration increased, the severity of pain also 
increased, suggesting that early detection and treatment 
are vital for managing LBP.
In a study on the degree of dysfunction in 1,760 patients 
with CLBP using the QBPDS [28], patients with CLBP 
had severe dysfunction with a mean score of 51.7±15.6 
points, which was similar to the degree of dysfunction in 
the NLBP patients in our study. NP caused by a lesion or 
dysfunction affecting the nervous system [4] can increase 
pain and reduce physical activity [19,29]. 
Korean patients with CLBP had a much lower QoL than 
patients with other chronic diseases [18]. According to 
our study, patients with CLBP and NP have an even worse 
QoL than those without NP. Recent studies have reported 
that NP can adversely affect patients’ overall QoL [30] 
because NP hampers functional movements and amplifies 
depression, which interferes with proper self-management 
and daily life [8]. It is reasonable to conclude that the 
combination of NP and CLBP leads to poorer outcomes 
than either condition by itself. Further, failures in early 
pain control measures or a lack of targeted treatment 
might have exacerbated outcomes in our patients.
Therefore, to administer the appropriate treatment and 
motor rehabilitation regimen for each individual that 
ultimately will restore normal functionality and improve 
the QoL, the underlying NP mechanism in patients with 
NLBP must be identified. 
1. Clinical significance of this study 
A large-scale epidemiologic study of 1,200 patients from 
27 general hospitals was conducted to investigate NP 
prevalence in adults with CLBP in Korea. To our knowl-
edge, there have been no other similar studies conducted 
in a Korean population. The results of the QoL and degree 
of dysfunction surveys suggest that patients with CLBP 
should be screened for NP and that the choice of therapy 
should be based on the underlying NP mechanism.
2. Limitations of this study
There are several limitations. One is various disease cat-
egories that we included, such as LBP and radiculopathy, 
which might have confounded the results. Further, be-
cause this is a cross-sectional study, we were unable to 
evaluate the temporal and causal relationships between 
patient characteristics and NP prevalence.
Conclusions
NP was highly prevalent in Korean patients with CLBP. 
In particular, NP prevalence was higher in males and in 
patients who had radiating and severe pain. In addition, 
patients with CLBP having NP had a lower QoL and more 
severe dysfunction than those without NP. Therefore, pa-
tients with such characteristics should be carefully exam-
ined for NP, and the underlying mechanism of NP should 
Jin-Hwan Kim et al.926 Asian Spine J 2017;11(6):917-927
be identified to administer the appropriate treatment for 
NLBP.
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